Dear Editor,We have read the Letter to the Editor by Vlayen *et al*. carefully. We apologize for the wrongly extracted data in our meta-analysis.[@b1] The 1-year overall survival (OS) rate in the Dutch trial by Kramer *et al*.[@b2] was 19.6% for the high-dose group and 10.9% for the low-dose group. We have redone the statistical analysis. The below paragraph shows the corrected results and our conclusion was also revised as: "This meta-analysis indicates that high-dose (≥30 Gy) radiotherapy provides higher 1-year OS rate than low-dose (\<30 Gy) radiotherapy in patients with locally advanced lung cancer; however, the symptom palliation and 2-year OS are similar between high-dose and low-dose radiotherapy."

Overall survival rate
=====================

The forest plot of the meta-analysis for the 1-year OS rate is presented in Fig.[1](#fig01){ref-type="fig"}. After pooling of the data, no significant heterogeneity among the studies was found (*Q* = 3.07, d.f. = 4*, P* = 0.547; *I*^2^ = 0.0%); therefore, a fixed-effects model was used for the meta-analysis of the 1-year OS rate. The combined odd ratios (ORs) revealed significant difference in 1-year OS between patients treated with a higher radiotherapy dose compared to those treated with a lower dose. Among the five studies, ORs ranged from 1.04 to 1.99, with the combined OR = 1.28 (95% confidence interval, 1.03--1.60; *P* = 0.029; Fig.[1](#fig01){ref-type="fig"}).

![Forest plots of the meta-analysis comparing higher dose ( ≥ 30 Gy) versus lower dose ( \< 30 Gy) radiotherapy for 1-year overall survival (OS) in locally advanced lung cancer.](cas0106-0783-f1){#fig01}
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